Table 3.
BP patients (n = 13) | |
---|---|
Age (years) median (IQR) | 57 (51-71.5) |
Sex (female/male) | 7/6 |
Female age (years) median (IQR) | 56 (46-62) |
Male age (years) median (IQR) | 71.5 (51.5-79.25) |
Disease duration (months) median (IQR) | 2 (1-3.5) |
Previous history, n (%) | 5 (38.5) |
Hypertension, n (%) | 4 (30.8) |
Cerebrovascular disease, n (%) | 2 (15.4) |
miR-1291 (2-ΔCt), median (IQR), n = 13 | |
Baseline | 0.74 (0.28-2.66) |
Disease control stage | 0.19 (0.08-0.50) |
CCL17 (pg/mL) median (IQR), n = 13 | |
Baseline | 1557 (387-5906) |
Disease control stage | 246.3 (86.4-514.2) |
Anti‐BP180 > 9 U/mL, median (IQR), n = 10 | |
Baseline | 103.5 (66.08-168.2) |
Disease control stage | 18.09 (4.80-48.58) |
Anti‐BP230 > 9 U/mL, median (IQR), n = 9 | |
Baseline | 80.87 (27.32-102.9) |
Disease control stage | 21.61 (2.65-59.63) |